Search

Your search keyword '"S1p1"' showing total 200 results

Search Constraints

Start Over You searched for: Descriptor "S1p1" Remove constraint Descriptor: "S1p1"
200 results on '"S1p1"'

Search Results

1. Co-modulation of T cells and B cells enhances the inhibition of inflammation in experimental hypersensitivity pneumonitis

2. Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine.

Catalog

Books, media, physical & digital resources

3. Characterization of the Sphingolipidome of the Peri-Infarct Tissue during Hemorrhagic Transformation in a Mouse Model of Cerebral Ischemia.

4. Co-modulation of T cells and B cells enhances the inhibition of inflammation in experimental hypersensitivity pneumonitis.

5. Microglia Contributes to BAF-312 Effects on Blood–Brain Barrier Stability.

6. Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod.

7. Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod

8. Sphingosine 1-phosphate receptor-1 in cardiomyocytes is required for normal cardiac development

9. A label‐free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P1 agonists

10. Deletion of Sphingosine 1‐Phosphate receptor 1 in cardiomyocytes during development leads to abnormal ventricular conduction and fibrosis

11. Deletion of Sphingosine 1‐Phosphate receptor 1 in cardiomyocytes during development leads to abnormal ventricular conduction and fibrosis.

12. In silico Docking Studies of Fingolimod and S1P1 Agonists

13. El receptor S1P1 de la esfingosina1-fosfato: avances en el conocimiento de su estructura, función e importancia biomédica.

14. A label‐free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P1 agonists.

15. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.

16. In silico Docking Studies of Fingolimod and S1P1 Agonists.

17. Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis

19. A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models.

20. Crosstalk between Fas and S1P1 signaling via NF-kB in osteoclasts controls bone destruction in the TMJ due to rheumatoid arthritis.

21. Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis.

22. Impact of S1P Mimetics on Mesenteric Ischemia/Reperfusion Injury

23. Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma

24. Identification of Sphingosine 1-Phosphate Receptor Subtype 1 (S1P1) as a Pathogenic Factor in Transient Focal Cerebral Ischemia.

25. Induced Regulatory T Cells Superimpose Their Suppressive Capacity with Effector T Cells in Lymph Nodes via Antigen-Specific S1p1-Dependent Egress Blockage

26. CCN2 Mediates S1P-Induced Upregulation of COX2 Expression in Human Granulosa-Lutein Cells

27. Microglia Contributes to BAF-312 Effects on Blood-Brain Barrier Stability

28. Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study.

29. CD69: from activation marker to metabolic gatekeeper.

30. Sphingosine-1-Phosphate-Specific G Protein-Coupled Receptors as Novel Therapeutic Targets for Atherosclerosis

31. Sphingosine kinase-1 is overexpressed and correlates with hypoxia in osteosarcoma: relationship with clinicopathological parameters

32. S1P1 downregulation tailors CD8+ T-cell residence time in lymph nodes to the strength of the antigenic stimulation.

33. Crosstalk between Fas and S1P1 signaling via NF-kB in osteoclasts controls bone destruction in the TMJ due to rheumatoid arthritis

34. El receptor S1P1 de la esfingosina1-fosfato: avances en el conocimiento de su estructura, función e importancia biomédica

35. Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.

37. Protective effect of the sphingosine-1 phosphate receptor agonist siponimodon disrupted blood brain barrier function

38. Piperazinyl-oxadiazoles as selective sphingosine-1-phosphate receptor agonists.

39. The anticoagulant activated protein C (aPC) promotes metaplasticity in the hippocampus through an EPCR-PAR1-S1P1 receptors dependent mechanism.

40. Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis.

41. Second generation S1P pathway modulators: Research strategies and clinical developments.

42. S1P lyase in thymic perivascular spaces promotes egress of mature thymocytes via up-regulation of S1P receptor 1.

43. Evaluation of commercial antibodies against human sphingosine-1-phosphate receptor 1.

44. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis

45. Correction: First use of cenerimod, a selective S1P

46. In silico Docking Studies of Fingolimod and S1P1 Agonists

47. T Cell Egress from the Thymus via Corticomedullary Blood Vessels

48. Isoforms of protein kinase C involved in phorbol ester-induced sphingosine 1-phosphate receptor 1 phosphorylation and desensitization.

49. Gastric Parietal Cell Atrophy and Depletion after Administration of a Sphingosine-1-Phosphate 1 Inhibitor.

50. Predictability of Peripheral Lymphocyte Reduction of Novel S1P1 Agonists by In Vitro GPCR Signaling Profile.